Tonix Pharmaceuticals Holding (TNXP) Cash from Financing Activities (2010 - 2026)

Tonix Pharmaceuticals Holding's Cash from Financing Activities history runs 16 years deep, the most recent figure standing at $20.2 million for Q1 2026.

• On a quarterly basis, Cash from Financing Activities fell 59.21% year-over-year to $20.2 million in Q1 2026; TTM through Mar 2026 was $185.2 million, a 0.32% change from a year earlier, with the FY2025 full-year figure at $214.5 million, up 59.06% from the prior year.
• Cash from Financing Activities slipped to $20.2 million in Q1 2026 per TNXP's latest filing, from $59.1 million in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $94.9 million in Q3 2025 and bottomed at -$11.5 million in Q1 2023.
• The 5-year median for Cash from Financing Activities is $13.1 million (2022), against an average of $29.1 million.
• Across the five-year window, Cash from Financing Activities sank 188.03% in 2023 and soared 23464.62% in 2025, its largest moves.
• Year by year, Cash from Financing Activities stood at $7.2 million in 2022, then surged by 463.2% to $40.7 million in 2023, then jumped by 109.15% to $85.2 million in 2024, then slumped by 30.55% to $59.1 million in 2025, then sank by 65.84% to $20.2 million in 2026.
• Per Business Quant, the three latest TNXP Cash from Financing Activities figures stand at $20.2 million (Q1 2026), $59.1 million (Q4 2025), and $94.9 million (Q3 2025).